This may be explained by additional everolimus-mediated mTORC1 inhibition rendering cells more sensitive to BYL719, as previously reported for breast cancer cells [38], and BYL719-mediated prevention of everolimus-induced AKT activation [16–18], as now shown in our cells. Here, AKT1 is linked to breast carcinoma.